News

CGeneTech: The first domestic original DPP-4 inhibitor, Shengliptin, is "exempted from two into three"

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-11-14
  • Views:0

(Summary description)Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

CGeneTech: The first domestic original DPP-4 inhibitor, Shengliptin, is "exempted from two into three"

(Summary description)Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2019-11-14
  • Views:0

Today is the 13th "United Nations Diabetes Day", and we have good news from B Village Guest: CGeneTech, which focuses on the research and development of new glucose-lowering drugs, announced that its new glucose-lowering drug, DPP-4 inhibitor Shengliptin phosphate, has been officially approved by the National Center for Drug Review, exempting it from Phase II clinical trials and entering Phase III trials directly, which will promote the first domestic This will facilitate the early launch of the first domestic original DPP-4 inhibitor drug for the benefit of Chinese diabetic patients as soon as possible.

The theme of the 2019 United Nations Diabetes Day is "Prevent and Control Diabetes, Protect Your Family", advocating healthy lifestyles and regular testing, and the whole society to take action together to pay attention to diabetes. At present, the situation of diabetes prevention and control worldwide is still serious. According to the World Health Organization's statistical forecast, the number of people with diabetes worldwide reached 422 million in 2017. Among them, 114 million people have the disease in China, which is already more than a quarter of the global total. In the foreseeable future (2020-2030), with the aging of the population, the number of people with the disease will increase to different degrees in all regions of the world. The resulting medical costs are also increasing year by year, imposing a heavy financial burden on patients' families and society.

Opening speech and concluding remarks by Prof. Ji Linong

 

CGeneTech (Suzhou, China) Co., Ltd. is an innovative technology company dedicated to the research and development of hypoglycemic drugs. "In 2012 and 2018, Shengliptin was selected as one of the major new drug creation projects in the 12th and 13th Five-Year Plans. The data from a large sample size clinical phase I trial completed this year showed that the efficacy of Centigliptin phosphate in type 2 diabetes is promising, safe and reliable compared with the positive control drug selegiline. At present, Shenggliptin phosphate has received formal approval from the National Center for Drug Review to be exempted from the Phase II clinical trial and enter the Phase III trial directly.


  Recently, in Beijing, where autumn is enchanting in the midst of all the beauty, CGeneTech successfully held a phase III clinical trial investigator meeting on the combination of Shengliptin phosphate tablets and metformin for the treatment of type 2 diabetes, with a total of 116 investigators from 50 large clinical research centers and endocrinology departments across China attending the meeting. The meeting was chaired by Prof. Ji Linong from Peking University People's Hospital, and experts at the meeting conducted in-depth communication and discussion on the details of phase III trial design and clinical implementation. Prof. Zhao Weigang from Peking Union Medical College Hospital and other participating investigators not only highly affirmed the results of the phase I clinical study of Shengliptin phosphate, but also made valuable suggestions for the phase III clinical trial. As the lead PI of this trial, Prof. Lignon Ji not only communicated with the participants at the academic level, but also concluded that the core R&D team of CGeneTech comes from the best chemistry department in China - the chemistry department of Peking University, and Shenggliptin phosphate has been continuously supported by the key innovative drugs at the national level. As the first home-made original DPP-4 inhibitor, Shengliptin will certainly have a great impact on the domestic diabetes drug market, benefiting the general public. Meanwhile, Prof. Ji also took this opportunity to invite more experts in the field of diabetes to attend another Investigator Conference on the Phase III trial of Shengliptin phosphate monotherapy for type 2 diabetes to be held in Beijing on the morning of December 19, 2019.

 

Group photo of all participating researchers

 

Ding Torping, the chairman of CGeneTech, said he expects that new and good drugs such as Shengliptin phosphate will come into the lives of diabetic patients as soon as possible to better help them. The road to drug creation is difficult, technology is the first. Under the prosperous times, the country will be safe and secure.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO